Insider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Purchases 9,289 Shares of Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Michael Catelani purchased 9,289 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was acquired at an average price of $2.15 per share, for a total transaction of $19,971.35. Following the acquisition, the chief financial officer now directly owns 44,500 shares of the company’s stock, valued at $95,675. This trade represents a 26.38 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Anixa Biosciences Stock Performance

Shares of NASDAQ:ANIX opened at $2.58 on Friday. The business’s 50-day simple moving average is $2.84 and its 200 day simple moving average is $3.02. The company has a market cap of $83.02 million, a P/E ratio of -6.62 and a beta of 0.90. Anixa Biosciences, Inc. has a one year low of $2.07 and a one year high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. Analysts predict that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANIX. Concorde Asset Management LLC purchased a new position in Anixa Biosciences in the 2nd quarter valued at about $31,000. International Assets Investment Management LLC increased its position in shares of Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after acquiring an additional 23,800 shares during the last quarter. Tyler Stone Wealth Management lifted its stake in shares of Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after acquiring an additional 21,008 shares in the last quarter. Virtu Financial LLC purchased a new position in Anixa Biosciences in the third quarter valued at about $34,000. Finally, Westside Investment Management Inc. grew its stake in Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares in the last quarter. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, November 19th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Tuesday.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.